TCT 2026: PROGRESS Trial Shows Benefit for TAVI in Moderate AS

Edwards’ PROGRESS Trial Shows TAVR as Superior to Clinical Surveillance in Moderate AS

November 2, 2026—Edwards Lifesciences announced that the randomized PROGRESS trial met its primary endpoint, demonstrating superiority of transcatheter aortic valve replacement (TAVR) over clinical surveillance in patients with moderate aortic stenosis (AS) and at-risk features, including symptoms, cardiac damage, or dysfunction. The results were presented as late-breaking data at TCT 2026 and simultaneously published in The New England Journal …

Earlier Valve Replacement Benefits Some Patients With Moderate Aortic Stenosis

Patients with moderate aortic stenosis, a narrowing of the heart’s aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.

TCT 2026: PROGRESS trial shows benefit for TAVI in moderate AS

Patients with moderate aortic stenosis (AS) undergoing transcatheter aortic valve intervention (TAVI) had improved outcomes at two years than those left under clinical surveillance, results of the PROGRESS trial, presented during a late-breaking trials session at the Transcatheter Cardiovascular Therapeutics (TCT) conference (31 October–3 November, San Diego, USA), have shown. PROGRESS, a prospective, multicentre, randomised, […]

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features